Occlutech Paravalvular Leak Device

Occlutech Uniform Occluder

Occlutech Perimembranous VSD Occluder

Occlutech muscular VSD Occluder

Pushing the boundaries in VSD closure

A track record of innovation, performance and safety

A track record of innovation, performance and safety.

Since developing the first unique Occlutech occluder in 2003, over 50,000 ASD and PFO occluders have been delivered to over 80 countries around the world. Occlutech’s track record regarding performance and safety is excellent while we are still dedicated to innovating and constantly improving our products.

Perfecting Performance

About Occlutech

Occlutech was founded in Germany in 2003, and has since developed into one of the world´s leading suppliers in the area of structural heart disease with products and projects for; congenital defects, stroke prevention, and heart failure.

The company´s products are sold in over 80 countries globally and the total number of implantations is approaching 100.000, setting the highest standards regarding quality, outcomes and patient safety.

Occlutech maintains direct sales and clinical support operations to hospitals and physicians in Canada and Europe. Throughout the rest of the world the company works through qualified distribution partners, many of them shareholders and long-term partners.

Occlutech operates R&D and manufacturing facilities at its original site in Jena, Germany and at an additional site in Istanbul, Turkey. From Helsingborg, Sweden the company runs its global marketing support, customer service and manages global sales.

Technology Driven

Occlutech combines several base technologies and expertise to create state-of-the-art cardiac and vascular implants. Technologies have been developed and patented by Occlutech in order to make a difference and allow better treatment of patients around the world. Occlutech wants to be at the forefront of new technologies and our R&D teams spend a lot of time discussing new treatment options for current and new therapeutic areas in the rapidly developing structural heart disease area.

Dedication to Innovation

Innovation is core to Occlutech´s ambition of serving our customers. Occlutech’s innovation has resulted in dozens of new products and projects and the creation of a patent portfolio consisting of hundreds of filed and issued patents in over 20 patent families. Our key customers are our most important source of ideas for new products and Occlutech has a strong ambition to be the most responsive industry partner when it comes to creating unique device solutions for previously unmet needs.

Superior Quality

Occlutech’s products are implanted in tens of thousands of human hearts every year. Obviously, quality and consistent performance of the products are key to the trust of thousands of physicians who use our products. Quality is key to Occlutech´s long-term success and we will never, ever compromise it.

Global Reach

Occlutech products are present world-wide and are implanted annually by thousands of physicians. In order to support physicians’ training and to have close contact with the world’s opinion leaders, Occlutech operates direct sales support organizations in the major European countries.

Governance and Ownership

Occlutech remains a private company and is not driven by short-term results or quarterly reporting pressures. A majority of Occlutech´s shareholders either work for the company as employees, or with the company as distribution partners around the world. This gives the shareholder base a genuine understanding both of the challenges, as well as the huge opportunities, in the field of structural heart disease and heart failure.

Perfecting Performance

Occlutech is dedicated to perfecting physicians’ performance around the world for the benefit of their patients on a daily basis. We work hard to provide the best service, superior quality products and superior performing devices, allowing treatment of the most complicated defects under challenging conditions, as well as quick and convenient products for day-to-day use.

Our products are not for sale in the US

Terms and ConditionsPrivacy PolicyCopyright NoticeIndividual product availability subject to local regulatory clearance, may not be available in all territories.Occlutech Atrial Flow Regulator (AFR) is under clinical investigation – not approved for sale.